Answers are grounded in this paper and cite their sources.
The ISCHEMIA trial cohort may not represent a high-risk population compared to other CCTA studies, potentially contextualizing the trial's findings regarding vulnerable plaque and MACE.
Comparison of annual major adverse cardiovascular events to other CCTA studies demonstrates the ISCHEMIA cohort was not comparatively high risk.
No takes yet. Share an insight, caveat, or question.
C. Noel Bairey Merz (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: